reglab/statecodes huggingface dataset:
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 14 - OSTEOPOROSIS PREVENTION EDUCATION ACT OF 1997 (§§ 20-15-1401 — 20-15-1404) › Section 20-15-1401 - Title

This subchapter may be cited as the "Osteoporosis Prevention Education Act of 1997".
Acts 1997, No. 732, § 1.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 14 - OSTEOPOROSIS PREVENTION EDUCATION ACT OF 1997 (§§ 20-15-1401 — 20-15-1404) › Section 20-15-1402 - Legislative findings

It is found and determined by the General Assembly that:
(1)
Osteoporosis, a bone-thinning disease, is a major public health problem that poses a threat to the health and quality of life of as many as twenty-five million (25,000,000) Americans;
(2)
The annual direct and indirect costs of osteoporosis to the healthcare system are estimated to be as high as eighteen billion dollars ($18,000,000,000) in 1993 and are expected to rise above sixty billion dollars ($60,000,000,000) in the year 2020;
(3)
Since osteoporosis progresses silently and currently has no cure, prevention, early diagnosis, and treatment are keys to reducing the prevalence of devastation from this disease;
(4)
Experts in the field of osteoporosis believe that with greater awareness of the value of prevention among medical experts, service providers, and the public, osteoporosis will be preventable and treatable in the future, thereby reducing the costs of long-term care and improving the quality of life for all Americans; and
(5)
Educating the public and the healthcare community throughout the State of Arkansas about this potentially devastating disease is of paramount importance and is in every respect in the public interest and to the benefit of all Arkansans.
Acts 1997, No. 732, § 2.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 14 - OSTEOPOROSIS PREVENTION EDUCATION ACT OF 1997 (§§ 20-15-1401 — 20-15-1404) › Section 20-15-1404 - Evaluation by the Department of Health

The Department of Health may evaluate any or all of the following:
(1)
The research on osteoporosis being conducted within the state;
(2)
The available technical assistance, educational materials, and osteoporosis programs nationwide;
(3)
The level of public and professional awareness about osteoporosis;
(4)
The needs of osteoporosis patients, their families, and their caregivers;
(5)
The needs of healthcare providers, including physicians, nurses, and managed care organizations, in regard to caring for the osteoporosis patient;
(6)
The services available to the osteoporosis patient;
(7)
The existence of osteoporosis treatment programs;
(8)
The existence of osteoporosis support groups; and
(9)
The existence of rehabilitation services for osteoporosis patients.
Acts 1997, No. 732, § 4.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 15 - UNIVERSAL NEWBORN HEARING SCREENING, TRACKING, AND INTERVENTION PROGRAM AND ADVISORY BOARD (§§ 20-15-1501 — 20-15-1505) › Section 20-15-1501 - Purpose

The purpose of this subchapter is to:
(1)
Provide early detection of hearing loss by physiological measurement in newborn children at the birthing facility or as soon after birth as possible;
(2)
Enable these children and their families and caregivers to obtain needed multidisciplinary evaluation, treatment, and intervention services at the earliest opportunity;
(3)
Prevent or mitigate the developmental delays and academic failures associated with late identification of hearing loss; and
(4)
Provide the state with the information necessary to effectively plan, establish, and evaluate a comprehensive system of appropriate services for newborns and infants who have a hearing loss or are deaf.
Acts 1999, No. 1559, § 1.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 15 - UNIVERSAL NEWBORN HEARING SCREENING, TRACKING, AND INTERVENTION PROGRAM AND ADVISORY BOARD (§§ 20-15-1501 — 20-15-1505) › Section 20-15-1502 - Definitions

As used in this subchapter:
(1)
"Birth admission" means the time after birth that the newborn remains in the hospital nursery before discharge;
(2)
"Birthing hospital" means any hospital located within the State of Arkansas that delivers newborns;
(3)
"Follow-up care" and "follow-up screening" mean the follow-up services provided by a licensed audiologist to diagnose a hearing loss;
(4)
"Hearing loss" means an impairment that is a dysfunction of the auditory system of any type or degree sufficient to interfere with acquisition and development of speech and language skills;
(5)
"Hearing screening" means a bilateral physiological measurement of hearing on a newborn or infant;
(6)
"Infant" means a child thirty (30) days to twelve (12) months old;
(7)
"Intervention" means amplification by a licensed audiologist as required and early intervention services described in Part H of the Individuals with Disabilities Education Act as in effect January 1, 1999;
(8)
"Newborn" means a child up to twenty-nine (29) days old;
(9)
"Parent" means a natural parent, stepparent, adoptive parent, legal guardian, or other legal custodian of a child;
(10)
"Program" means the Newborn Infant Hearing Screening Program; and
(11)
"Provider" means an audiologist licensed by the State of Arkansas who administers initial newborn and infant hearing screenings upon referral from a hospital or physician or follow-up screenings outside of the hospital setting.
Amended by Act 2019, No. 389,§ 33, eff. 7/24/2019.
Amended by Act 2019, No. 910,§ 5006, eff. 7/1/2019.
Acts 1999, No. 1559, § 2.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 15 - UNIVERSAL NEWBORN HEARING SCREENING, TRACKING, AND INTERVENTION PROGRAM AND ADVISORY BOARD (§§ 20-15-1501 — 20-15-1505) › Section 20-15-1504 - Testing - Results

(a)
After July 30, 1999, and promulgation of rules, every birthing hospital in this state with more than fifty (50) births per year shall provide or arrange for a bilateral physiological hearing screening on each birth admission. Medicaid shall reimburse the birthing hospital for the physiological screening with the reimbursement equal to that amount paid outpatient providers for the same service in addition to the current rate of per diem paid to the hospital.
(b)
Any birthing hospital, provider, or physician administering initial hearing screenings to newborns and infants shall forward test results on a screening report to the Department of Health by the fifteenth day of the month following the month in which the test was conducted.
(c)
Any birthing hospital, provider, or physician screening newborns and infants shall provide information on locations at which medical and audiological follow-up care and follow-up screening can be obtained by the parents or guardians of the newborns and infants.
(d)
All providers or physicians completing follow-up screening or follow-up care for the hearing impairment shall forward test results on a screening report to the department by the fifteenth day of the month following the month in which the test was conducted.
Amended by Act 2019, No. 315,§ 1948, eff. 7/24/2019.
Acts 1999, No. 1559, § 4.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 15 - UNIVERSAL NEWBORN HEARING SCREENING, TRACKING, AND INTERVENTION PROGRAM AND ADVISORY BOARD (§§ 20-15-1501 — 20-15-1505) › Section 20-15-1505 - Exemption

No test is to be performed if the parent of a newborn or infant dissents on the ground that the test conflicts with a personal religious belief or practice.
Acts 1999, No. 1559, § 5.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 17 - COLORECTAL CANCER ACT OF 2005 (§ 20-15-1701) › Section 20-15-1701 - et seq - [Repealed]

Acts 2005, No. 2236, § 1; repealed by Acts 2009, No. 1374, §2.
Acts 2009, No. 1374, §2 effective when funds are appropriated and available for the grant program created in Section 1 of the act.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 18 - ARKANSAS HIV-AIDS MINORITY TASK FORCE ACT OF 2007 (§§ 20-15-1801 — 20-15-1805) › Section 20-15-1801 - [Repealed]

Repealed by Act 2017, No. 540,§ 46, eff. 8/1/2017.
Acts 2007, No. 842, § 1.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 18 - ARKANSAS HIV-AIDS MINORITY TASK FORCE ACT OF 2007 (§§ 20-15-1801 — 20-15-1805) › Section 20-15-1802 - [Repealed]

Repealed by Act 2017, No. 540,§ 46, eff. 8/1/2017.
Acts 2007, No. 842, § 1.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 18 - ARKANSAS HIV-AIDS MINORITY TASK FORCE ACT OF 2007 (§§ 20-15-1801 — 20-15-1805) › Section 20-15-1803 - [Repealed]

Repealed by Act 2017, No. 540,§ 46, eff. 8/1/2017.
Amended by Act 2013, No. 1132,§ 15, eff. 8/16/2013.
Acts 2007, No. 842, § 1; 2009, No. 1484, § 7; 2011, No. 1230, § 1.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 18 - ARKANSAS HIV-AIDS MINORITY TASK FORCE ACT OF 2007 (§§ 20-15-1801 — 20-15-1805) › Section 20-15-1804 - [Repealed]

Repealed by Act 2017, No. 540,§ 46, eff. 8/1/2017.
Acts 2007, No. 842, § 1.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 18 - ARKANSAS HIV-AIDS MINORITY TASK FORCE ACT OF 2007 (§§ 20-15-1801 — 20-15-1805) › Section 20-15-1805 - [Repealed]

Repealed by Act 2017, No. 540,§ 46, eff. 8/1/2017.
Acts 2007, No. 842, § 2.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 19 - ARKANSAS COLORECTAL CANCER SCREENING INITIATIVE ACT (§§ 20-15-1901 — 20-15-1908) › Section 20-15-1901 - Title

This subchapter shall be known and may be cited as the "Arkansas Colorectal Cancer Screening Initiative Act".
Amended by Act 2019, No. 655,§ 1, eff. 7/24/2019.
Amended by Act 2017, No. 516,§ 1, eff. 8/1/2017.
Acts 2009, No. 1374, § 1.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 19 - ARKANSAS COLORECTAL CANCER SCREENING INITIATIVE ACT (§§ 20-15-1901 — 20-15-1908) › Section 20-15-1903 - Definition

As used in this subchapter, "high risk" means:
(1)
An individual over forty-five (45) years of age or who faces a high risk for colorectal cancer because of:
(A)
The presence of one (1) or more polyps on a previous colonoscopy, barium enema, or flexible sigmoidoscopy;
(B)
Family history of colorectal cancer;
(C)
Genetic alterations of hereditary nonpolyposis colon cancer or familial adenomatous polyposis;
(D)
Personal history of colorectal cancer, ulcerative colitis, or Crohn's disease; or
(E)
The presence of any appropriate recognized gene markers for colorectal cancer or other predisposing factors; and
(2)
Any additional or expanded definition of "persons at high risk for colorectal cancer" as recognized by medical science and determined by the Secretary of the Department of Health in consultation with the University of Arkansas for Medical Sciences.
Amended by Act 2019, No. 655,§ 1, eff. 7/24/2019.
Amended by Act 2019, No. 910,§ 5007, eff. 7/1/2019.
Amended by Act 2017, No. 516,§ 1, eff. 8/1/2017.
Acts 2009, No. 1374, § 1.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 19 - ARKANSAS COLORECTAL CANCER SCREENING INITIATIVE ACT (§§ 20-15-1901 — 20-15-1908) › Section 20-15-1904 - Initiative for prevention of colorectal cancer

(a)
There is created the Arkansas Colorectal Cancer Screening Initiative in the Department of Health, if funds are available.
(b)
The Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences may collaborate with the department and the Arkansas Cancer Coalition in conducting the initiative, which shall be administered through the department.
(c)
(1)
The initiative shall be designed in conformity with federal law and regulations regarding a program for prevention, early detection, and treatment of colorectal cancer.
(2)
Funds shall not be used to supplant funds already available for prevention, early detection, and treatment of colorectal cancer.
(d)
A contract may be made under this subchapter only if:
(1)
In providing screenings for colorectal cancer, priority is given to individuals who lack adequate coverage under health insurance and health plans for screenings for colorectal cancer;
(2)
Screenings are carried out as preventive health measures in accordance with evidence-based screening guidelines and procedures;
(3)
A payment made through the initiative for a screening procedure will not exceed the amount specified under federal law and regulations regarding a grant program for prevention, early detection, and treatment of colorectal cancer;
(4)
Funds shall not be spent to make payment for any item or service if that payment has been made or can reasonably be expected to be made:
(A)
Under a state compensation program, an insurance policy, or a federal or state health benefits program; or
(B)
By an entity that provides health services on a prepaid basis; and
(5)
Fiscal controls and fund accounting procedures are established to ensure proper disbursal of and accounting for amounts received under this subchapter.
(e)
Upon request, the department shall provide records maintained under this subchapter to the appropriate federal oversight agency.
(f)
The initiative shall be implemented statewide.
Amended by Act 2019, No. 655,§ 1, eff. 7/24/2019.
Amended by Act 2017, No. 516,§ 1, eff. 8/1/2017.
Acts 2009, No. 1374, § 1.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 19 - ARKANSAS COLORECTAL CANCER SCREENING INITIATIVE ACT (§§ 20-15-1901 — 20-15-1908) › Section 20-15-1905 - Initiative requirements

The Arkansas Colorectal Cancer Screening Initiative funded under this subchapter shall:
(1)
Provide screenings and diagnostic tests for colorectal cancer to individuals who are:
(A)
Forty-five (45) years of age or older; or
(B)
Under forty-five (45) years of age and at high risk for colorectal cancer;
(2)
Provide appropriate case management and referrals for medical treatment of individuals screened under the initiative created in this subchapter;
(3)
Directly or through coordination or an arrangement with healthcare providers or programs ensure the full continuum of follow-up and cancer care for individuals screened in the initiative, including without limitation:
(A)
Appropriate follow-up for abnormal test results;
(B)
Diagnostic services;
(C)
Therapeutic services; and
(D)
Treatment of detected cancers and management of unanticipated medical complications;
(4)
Carry out activities to improve the education, training, and skills of health professionals, including allied health professionals in the detection and control of colorectal cancer;
(5)
Establish mechanisms to monitor the quality of screening and diagnostic follow-up procedures for colorectal cancer;
(6)
Create and implement appropriate monitoring systems to monitor, including without limitation:
(A)
The number of facilities in the state that provide screening services in accordance with evidence-based screening guidelines and procedures;
(B)
Physicians, including family practitioners, gastroenterologists, and surgical endoscopists who perform colonoscopies in the state and the regions of the state in which the physicians practice;
(C)
Differences in cost across facilities as compared to Medicare payment for procedures; and
(D)
Available resources for follow-up diagnostics and treatment as needed;
(7)
Develop and disseminate findings derived from the monitoring systems;
(8)
Develop and disseminate public information and education programs for the detection and control of colorectal cancer and for promoting the benefits of receiving screenings for the public and for healthcare professions, to include without limitation education concerning:
(A)
High-risk populations;
(B)
Target populations; and
(C)
The uninsured and underinsured;
(9)
Develop provider-oriented programs to promote routine implementation of screening guidelines and patient-oriented programs to increase utilization of screening and diagnostic services; and
(10)
Make records of initiative activities and expenditures available to the Department of Health.
Amended by Act 2019, No. 655,§ 1, eff. 7/24/2019.
Amended by Act 2017, No. 516,§ 1, eff. 8/1/2017.
Acts 2009, No. 1374, § 1; 2011, No. 1121, § 4.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 19 - ARKANSAS COLORECTAL CANCER SCREENING INITIATIVE ACT (§§ 20-15-1901 — 20-15-1908) › Section 20-15-1906 - [Repealed]

Repealed by Act 2019, No. 655,§ 1, eff. 7/24/2019.
Amended by Act 2019, No. 910,§ 5008, eff. 7/1/2019.
Amended by Act 2017, No. 516,§ 1, eff. 8/1/2017.
Acts 2009, No. 1374, § 1.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 19 - ARKANSAS COLORECTAL CANCER SCREENING INITIATIVE ACT (§§ 20-15-1901 — 20-15-1908) › Section 20-15-1907 - [Repealed]

Repealed by Act 2019, No. 655,§ 1, eff. 7/24/2019.
Amended by Act 2017, No. 516,§ 1, eff. 8/1/2017.
Acts 2009, No. 1374, § 1.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 19 - ARKANSAS COLORECTAL CANCER SCREENING INITIATIVE ACT (§§ 20-15-1901 — 20-15-1908) › Section 20-15-1908 - [Repealed]

Repealed by Act 2019, No. 655,§ 1, eff. 7/24/2019.
Acts 2009, No. 1374, § 1.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 20 - DIABETES ACTION PLAN (§§ 20-15-2001 — 20-15-2003) › Section 20-15-2001 - Agency collaboration

The Department of Human Services and the Department of Health shall collaborate to identify goals and benchmarks while also developing individual entity plans to reduce the incidence of diabetes in Arkansas, improve diabetes care, and control complications associated with diabetes.
Added by Act 2015, No. 167,§ 1, eff. 7/22/2015.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 20 - DIABETES ACTION PLAN (§§ 20-15-2001 — 20-15-2003) › Section 20-15-2002 - Reporting

The Department of Human Services and the Department of Health shall submit a report to the Legislative Council by January 10 of each even-numbered year, including without limitation the following:
(1)
The financial impact and reach that diabetes of all types are having on each agency, localities, and the state, including without limitation:
(A)
The number of individuals with diabetes that are impacted or covered by the agency;
(B)
The number of individuals with diabetes and family members who are impacted by prevention and diabetes control programs implemented by the agency;
(C)
The financial toll or impact diabetes and its complications places on the program; and
(D)
The financial toll or impact diabetes and its complications places on the program in comparison to other chronic diseases and conditions;
(2)
An assessment of the benefits of implemented programs and activities that:
(A)
Aims at controlling diabetes and preventing the disease; and
(B)
Documents the amount and source for funding directed to the agency or entity from the General Assembly for programs and activities aimed at reaching individuals with diabetes;
(3)
A description of the level of coordination existing among the agencies and other entities of activities, programs, and messages on managing, treating, or preventing all forms of diabetes and its complications;
(4)
(A)
The development or revision of detailed action plans for battling diabetes with a range of actionable items for consideration by the General Assembly.
(B)
The plans shall identify:
(i)
Proposed actions to reduce the impact of diabetes, prediabetes, and related complications caused by diabetes;
(ii)
Expected outcomes of the actions proposed; and
(iii)
Benchmarks for controlling and preventing relevant forms of diabetes; and
(5)
The development of a detailed budget blueprint:
(A)
Identifying needs, costs, and resources required to implement the plan identified in subdivision (4) of this section; and
(B)
Including a budget range for all options presented in the plan identified in subdivision (4) of this section for consideration by the General Assembly.
Added by Act 2015, No. 167,§ 1, eff. 7/22/2015.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 20 - DIABETES ACTION PLAN (§§ 20-15-2001 — 20-15-2003) › Section 20-15-2003 - Applicability

The requirements of this subchapter are limited to the diabetes information, data, initiatives, and programs within each agency before July 22, 2015, unless there is available funding for diabetes in each agency that may be used for new research, data collection, reporting, or other requirements of this subchapter.
Added by Act 2015, No. 167,§ 1, eff. 7/22/2015.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 21 - RIGHT TO TRY ACT (§§ 20-15-2101 — 20-15-2111) › Section 20-15-2101 - Title

This subchapter shall be known and may be cited as the "Right to Try Act".
Added by Act 2015, No. 374,§ 1, eff. 7/22/2015.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 21 - RIGHT TO TRY ACT (§§ 20-15-2101 — 20-15-2111) › Section 20-15-2102 - Findings

It is found and determined by the General Assembly of the State of Arkansas that:
(1)
The process of approval for investigational drugs, biological products, and devices in the United States often takes many years;
(2)
Patients who have a terminal disease do not have the luxury of waiting until an investigational drug, biological product, or device receives final approval;
(3)
The standards of the United States Food and Drug Administration for the use of investigational drugs, biological products, and devices may deny the benefits of potentially life-saving treatments to terminally ill patients;
(4)
The State of Arkansas recognizes that patients who have a terminal disease have a fundamental right to attempt to pursue the preservation of their own lives by accessing available investigational drugs, biological products, and devices; and
(5)
The use of available investigational drugs, biological products, or devices is a decision that should be made by the patient with a terminal disease in consultation with his or her physician.
Added by Act 2015, No. 374,§ 1, eff. 7/22/2015.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 21 - RIGHT TO TRY ACT (§§ 20-15-2101 — 20-15-2111) › Section 20-15-2103 - Definitions

As used in this subchapter:
(1)
"Eligible patient" means a person who meets the requirements of eligibility in §
20-15-2104
;
(2)
"Investigational drug, biological product, or device" means a drug, biological product, or device that:
(A)
Has successfully completed phase I of clinical trials but has not been approved for general use by the United States Food and Drug Administration; and
(B)
Remains currently under investigation in a United States Food and Drug Administration clinical trial;
(3)
"Physician" means an individual licensed to practice medicine in the State of Arkansas under the Arkansas Medical Practices Act, §
17-95-201
et seq., §
17-95-301
et seq., and §
17-95-401
et seq.; and
(4)
"Terminal illness" means an incurable and irreversible condition that without the administration of life-sustaining treatment will, in the opinion of the patient's physician, result in death within a relatively short time.
Added by Act 2015, No. 374,§ 1, eff. 7/22/2015.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 21 - RIGHT TO TRY ACT (§§ 20-15-2101 — 20-15-2111) › Section 20-15-2104 - Eligibility

In order for a patient to access an investigational drug, biological product, or device under this subchapter, a physician must document in the patient's medical record and chart that the patient:
(1)
Has a terminal illness;
(2)
Has a determination from a qualified physician that the patient has no comparable or satisfactory treatment options approved by the United States Food and Drug Administration available to treat the terminal illness and that the probable risk to the patient from the investigational drug, biological product, or device is not greater than the probable risk from the terminal illness;
(3)
Has been unable to participate in a clinical trial for the terminal illness within one hundred (100) miles of the patient's home address or has not been accepted to the clinical trial within one (1) week of the completion of the clinical trial application process;
(4)
Has been given a prescription by a physician for an investigational drug, biological product, or device;
(5)
(A)
Has given informed consent in writing for the use of the investigational drug, biological product, or device.
(B)
If the patient is a minor or lacks the mental capacity to provide informed consent, a parent or legal guardian may provide informed consent on the patient's behalf; and
(6)
Has received written documentation from a physician that the patient meets the requirements of this subchapter.
Added by Act 2015, No. 374,§ 1, eff. 7/22/2015.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 21 - RIGHT TO TRY ACT (§§ 20-15-2101 — 20-15-2111) › Section 20-15-2105 - Availability

A manufacturer of an investigational drug, biological product, or device may, but is not required to, make its investigational drug, biological product, or device available to eligible patients under this subchapter.
Added by Act 2015, No. 374,§ 1, eff. 7/22/2015.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 21 - RIGHT TO TRY ACT (§§ 20-15-2101 — 20-15-2111) › Section 20-15-2106 - Costs - Definition

(a)
A manufacturer of an investigational drug, biological product, or device may:
(1)
Provide an investigational drug, biological product, or device to an eligible patient without receiving compensation; or
(2)
(A)
Require an eligible patient to pay the costs associated with the manufacture of the investigational drug, biological product, or device.
(B)
As used in this section, "costs associated with the manufacture of the investigational drug, biological product, or device" means the actual out-of-pocket costs incurred in providing the investigational drug, biological product, or device to the patient in the specific case.
(b)
If a patient dies while being treated by an investigational drug, biological product, or device, the patient's heirs are not liable for any outstanding debt to the manufacturer related to the investigational drug, biological product, or device.
Added by Act 2015, No. 374,§ 1, eff. 7/22/2015.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 21 - RIGHT TO TRY ACT (§§ 20-15-2101 — 20-15-2111) › Section 20-15-2107 - Insurance coverage

An insurance company:
(1)
May, but is not required to, provide coverage for an investigational drug, biological product, or device; and
(2)
Shall not deny coverage for an item or service that is otherwise covered by an insurance contract between the eligible person and an insurance company.
Added by Act 2015, No. 374,§ 1, eff. 7/22/2015.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 21 - RIGHT TO TRY ACT (§§ 20-15-2101 — 20-15-2111) › Section 20-15-2108 - Prohibited sanctions

The recommendation, prescription, treatment, or participation in the treatment of a terminal illness with an investigational drug, biological product, or device shall not permit:
(1)
A licensing board to revoke a license, fail to renew a license, or take any other action against a physician's license;
(2)
A state agency or licensing board to revoke a license, fail to renew a license, or take any other action against:
(A)
A medical professional licensed under state law; or
(B)
A hospital licensed under §
20-9-213
; or
(3)
An action against a hospital's Medicare certification.
Added by Act 2015, No. 374,§ 1, eff. 7/22/2015.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 21 - RIGHT TO TRY ACT (§§ 20-15-2101 — 20-15-2111) › Section 20-15-2109 - Remedy

The counseling, advice, or recommendation by a medical professional who is licensed under state law is not a violation of this subchapter.
Added by Act 2015, No. 374,§ 1, eff. 7/22/2015.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 21 - RIGHT TO TRY ACT (§§ 20-15-2101 — 20-15-2111) › Section 20-15-2110 - Immunity

(a)
Except in the case of gross negligence or willful misconduct, a person or entity that manufacturers, imports, distributes, prescribes, dispenses, administers, or is otherwise involved in the care of an eligible patient using an investigational drug, biological product, or device is immune from civil liability for any loss, damage, or injury arising out of, relating to, or resulting from the investigational drug, biological product, or device so long as the person or entity is substantially complying in good faith with this subchapter.
(b)
This subchapter does not require a medical professional who is licensed under the laws of this state to counsel, advise, prescribe, dispense, administer, or otherwise be involved in the care of an eligible patient using an investigational drug, biological product, or device.
(c)
This subchapter does not require a hospital licensed under §
20-9-213
to provide any service related to an investigational drug, biological product, or device.
Added by Act 2015, No. 374,§ 1, eff. 7/22/2015.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 21 - RIGHT TO TRY ACT (§§ 20-15-2101 — 20-15-2111) › Section 20-15-2111 - Medicaid coverage

This subchapter does not require the Department of Human Services or the Arkansas Medicaid Program to provide additional coverage for an investigational drug, biological product, or device.
Added by Act 2015, No. 374,§ 1, eff. 7/22/2015.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 22 - TASK FORCE ON ALPHA-GAL (§§ 20-15-2201 — 20-15-2203) › Section 20-15-2201 - Expired

Added by Act 2017, No. 570,§ 2, eff. 8/1/2017.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 22 - TASK FORCE ON ALPHA-GAL (§§ 20-15-2201 — 20-15-2203) › Section 20-15-2202 - Expired

Added by Act 2017, No. 570,§ 2, eff. 8/1/2017.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 22 - TASK FORCE ON ALPHA-GAL (§§ 20-15-2201 — 20-15-2203) › Section 20-15-2203 - Expired

Added by Act 2017, No. 570,§ 2, eff. 8/1/2017.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 23 - MATERNAL MORTALITY REVIEW COMMITTEE (§§ 20-15-2301 — 20-15-2307) › Section 20-15-2301 - Maternal Mortality Review Committee

(a)
(1)
The Department of Health shall establish the Maternal Mortality Review Committee to review maternal deaths and to develop strategies for the prevention of maternal deaths.
(2)
The committee shall be multidisciplinary and composed of members as deemed appropriate by the department.
(b)
The department may contract with an external organization to assist in collecting, analyzing, and disseminating maternal mortality information, organizing and convening meetings of the committee, and other tasks as may be incident to these activities, including providing the necessary data, information, and resources to ensure successful completion of the ongoing review required by this section.
Added by Act 2019, No. 829,§ 2, eff. 7/24/2019.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 23 - MATERNAL MORTALITY REVIEW COMMITTEE (§§ 20-15-2301 — 20-15-2307) › Section 20-15-2302 - Powers and duties

The Maternal Mortality Review Committee shall:
(1)
Review pregnancy-associated deaths or deaths of women with indication of pregnancy up to three hundred sixty-five (365) days after the end of pregnancy, regardless of cause, to identify the factors contributing to these deaths;
(2)
Identify maternal death cases;
(3)
Review medical records and other relevant data;
(4)
Contact family members and other affected or involved persons to collect additional relevant data;
(5)
Consult with relevant experts to evaluate the records and data;
(6)
Make determinations regarding the preventability of maternal deaths;
(7)
Develop recommendations for the prevention of maternal deaths, including public health and clinical interventions that may reduce these deaths and improve systems of care; and
(8)
Disseminate findings and recommendations to policy makers, healthcare providers, healthcare facilities, and the general public.
Added by Act 2019, No. 829,§ 2, eff. 7/24/2019.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 23 - MATERNAL MORTALITY REVIEW COMMITTEE (§§ 20-15-2301 — 20-15-2307) › Section 20-15-2303 - Access to records

(a)
Healthcare providers, healthcare facilities, and pharmacies shall provide reasonable access to the Maternal Mortality Review Committee to all relevant medical records associated with a case under review by the committee.
(b)
A healthcare provider, healthcare facility, or pharmacy providing access to medical records as described by subsection (a) of this section is not liable for civil damages or subject to any criminal or disciplinary action for good faith efforts in providing such records.
Added by Act 2019, No. 829,§ 2, eff. 7/24/2019.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 23 - MATERNAL MORTALITY REVIEW COMMITTEE (§§ 20-15-2301 — 20-15-2307) › Section 20-15-2304 - Confidentiality

(a)
(1)
Information, records, reports, statements, notes, memoranda, or other data collected under this subchapter are not admissible as evidence in any action of any kind in any court or before any other tribunal, board, agency, or person.
(2)
Information, records, reports, statements, notes, memoranda, or other data collected under this subchapter shall not be exhibited or disclosed in any way, in whole or in part, by any officer or representative of the Department of Health or any other person, except as necessary for the purpose of furthering the review of the Maternal Mortality Review Committee of the case to which they relate.
(3)
A person participating in a review shall not disclose, in any manner, the information so obtained except in strict conformity with such review project.
(b)
All information, records of interviews, written reports, statements, notes, memoranda, or other data obtained by the department, the committee, and other persons, agencies, or organizations so authorized by the department under this subchapter are confidential.
(c)
(1)
All proceedings and activities of the committee under this subchapter, opinions of members of the committee formed as a result of such proceedings and activities, and records obtained, created, or maintained pursuant to this subchapter, including records of interviews, written reports, and statements procured by the department or any other person, agency, or organization acting jointly or under contract with the department in connection with the requirements of this subchapter, are confidential and are not subject to the Freedom of Information Act of 1967, §
25-19-101
et seq., relating to open meetings, subject to subpoena, discovery, or introduction into evidence in any civil or criminal proceeding.
(2)
However, this subchapter does not limit or restrict the right to discover or use in any civil or criminal proceeding anything that is available from another source and entirely independent of the committee's proceedings.
(d)
(1)
Members of the committee shall not be questioned in any civil or criminal proceeding regarding the information presented in or opinions formed as a result of a meeting or communication of the committee.
(2)
This subchapter does not prevent a member of the committee from testifying to information obtained independently of the committee or which is public information.
Added by Act 2019, No. 829,§ 2, eff. 7/24/2019.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 23 - MATERNAL MORTALITY REVIEW COMMITTEE (§§ 20-15-2301 — 20-15-2307) › Section 20-15-2305 - Disclosure

Disclosure of protected health information is allowed for public health, safety, and law enforcement purposes, and providing case information on maternal deaths for review by the Maternal Mortality Review Committee is not a violation of the Health Insurance Portability and Accountability Act of 1996.
Added by Act 2019, No. 829,§ 2, eff. 7/24/2019.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 23 - MATERNAL MORTALITY REVIEW COMMITTEE (§§ 20-15-2301 — 20-15-2307) › Section 20-15-2306 - Immunity from liability

State, local, or regional committee members are immune from civil and criminal liability in connection with their good faith participation in the maternal death review and all activities related to a review with the Maternal Mortality Review Committee.
Added by Act 2019, No. 829,§ 2, eff. 7/24/2019.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 23 - MATERNAL MORTALITY REVIEW COMMITTEE (§§ 20-15-2301 — 20-15-2307) › Section 20-15-2307 - Reporting

(a)
Beginning in 2020, the Maternal Mortality Review Committee shall file a written report on the number and causes of maternal deaths and its recommendations on or before December 31 of each year to:
(1)
The Senate Committee on Public Health, Welfare, and Labor;
(2)
The House Committee on Public Health, Welfare, and Labor; and
(3)
The Legislative Council.
(b)
The report shall include:
(1)
The findings and recommendations of the Maternal Mortality Review Committee; and
(2)
An analysis of factual information obtained from the review of the maternal death investigation reports and any local or regional review panels that do not violate the confidentiality provisions under this subchapter.
(c)
The report shall include only aggregate data and shall not identify a particular facility or provider.
Added by Act 2019, No. 829,§ 2, eff. 7/24/2019.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 24 - MATERNAL AND PERINATAL OUTCOMES QUALITY REVIEW COMMITTEE (§§ 20-15-2401 — 20-15-2407) › Section 20-15-2401 - Maternal and Perinatal Outcomes Quality Review Committee

(a)
(1)
The Department of Health shall establish the Maternal and Perinatal Outcomes Quality Review Committee to review data on births and to develop strategies for improving birth outcomes.
(2)
The committee shall be multidisciplinary and composed of members as deemed appropriate by the department.
(b)
The department may contract with an external organization to assist in collecting, analyzing, and disseminating maternal mortality information, organizing and convening meetings of the committee, and other tasks as may be incident to these activities, including providing the necessary data, information, and resources to ensure successful completion of the ongoing review required by this section.
Added by Act 2019, No. 1032,§ 2, eff. 7/24/2019.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 24 - MATERNAL AND PERINATAL OUTCOMES QUALITY REVIEW COMMITTEE (§§ 20-15-2401 — 20-15-2407) › Section 20-15-2402 - Powers and duties

The Maternal and Perinatal Outcomes Quality Review Committee shall:
(1)
Create a unified message and strategy that builds on best practices;
(2)
Develop clear measurements to evaluate targeted outreach, progress, and return on investment;
(3)
Develop recommendations for levels of care by establishing systems designating where infants are born or transferred according to the level of care they need at birth;
(4)
Create a system of continuous quality improvement that will include the ability of designated and nondesignated hospitals to compare performance to peer facilities;
(5)
Create a collaborative framework, in addition to quality improvement for birthing hospitals that will allow for better outcomes, better overall long-term care, and decreased cost of care; and
(6)
Disseminate findings and recommendations to policy makers, healthcare providers, healthcare facilities, and the general public.
Added by Act 2019, No. 1032,§ 2, eff. 7/24/2019.
Arkansas Code of 1987 (2023) › Title 20 - PUBLIC HEALTH AND WELFARE (§§ 20-2-101 — 20-86-113) › Subtitle 2 - HEALTH AND SAFETY (§§ 20-6-101 — 20-38-113) › Chapter 15 - DISEASE AND DISEASE PREVENTION GENERALLY (§§ 20-15-101 — 20-15-2407) › Subchapter 24 - MATERNAL AND PERINATAL OUTCOMES QUALITY REVIEW COMMITTEE (§§ 20-15-2401 — 20-15-2407) › Section 20-15-2403 - Access to records

(a)
Healthcare providers, healthcare facilities, and pharmacies shall provide reasonable access to the Maternal and Perinatal Outcomes Quality Review Committee to all relevant medical records associated with a case under review by the committee.
(b)
A healthcare provider, healthcare facility, or pharmacy providing access to medical records as described in subsection (a) of this section is not liable for civil damages or subject to any criminal or disciplinary action for good faith efforts in providing such records.
Added by Act 2019, No. 1032,§ 2, eff. 7/24/2019.